209 related articles for article (PubMed ID: 31277773)
1. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.
Pignot G; Loriot Y; Kamat AM; Shariat SF; Plimack ER
Eur Urol Oncol; 2019 Jul; 2(4):355-364. PubMed ID: 31277773
[TBL] [Abstract][Full Text] [Related]
2. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in the Elderly.
Lalani AA; Bossé D; McGregor BA; Choueiri TK
Eur Urol Focus; 2017 Oct; 3(4-5):403-412. PubMed ID: 29183736
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in genitourinary malignancies.
Mehta K; Patel K; Parikh RA
J Hematol Oncol; 2017 Apr; 10(1):95. PubMed ID: 28434403
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy advances in uro-genital malignancies.
Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
[TBL] [Abstract][Full Text] [Related]
6. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies.
Solanki AA; Bossi A; Efstathiou JA; Lock D; Mondini M; Ramapriyan R; Welsh J; Kang J
Eur Urol Oncol; 2019 Feb; 2(1):79-87. PubMed ID: 30929848
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
9. Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
Maisch P; Koll F; Bolenz C; Chun FK; Gschwend JE; Schmid SC
Urol Oncol; 2023 May; 41(5):219-232. PubMed ID: 36372634
[TBL] [Abstract][Full Text] [Related]
10. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
11. Novel immunotherapy combinations for genitourinary cancers.
Al Harthy M; Redman J; Madan RA
Expert Opin Biol Ther; 2020 Mar; 20(3):253-262. PubMed ID: 31914333
[TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy in genitourinary malignancies.
Hoffman-Censits J; Wilde L
Curr Opin Urol; 2016 Nov; 26(6):523-8. PubMed ID: 27517637
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Advances in Urothelial Carcinoma.
Jain RK; Snyders T; Nandagopal L; Garje R; Zakharia Y; Gupta S
Curr Treat Options Oncol; 2018 Dec; 19(12):79. PubMed ID: 30554335
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of checkpoint inhibition in localized bladder cancer.
Singh P; Black P
Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
[TBL] [Abstract][Full Text] [Related]
15. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic agents for genitourinary cancers.
Zarrabi K; Paroya A; Wu S
J Hematol Oncol; 2019 Sep; 12(1):89. PubMed ID: 31484560
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in genitourinary malignancies.
Thana M; Wood L
Curr Oncol; 2020 Apr; 27(Suppl 2):S69-S77. PubMed ID: 32368176
[TBL] [Abstract][Full Text] [Related]
18. Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review.
Williams SB; Ray-Zack MD; Hudgins HK; Oldenburg J; Trinh QD; Nguyen PL; Shore ND; Wirth MP; O'Brien T; Catto JWF
Eur Urol Oncol; 2019 May; 2(3):265-273. PubMed ID: 31200840
[TBL] [Abstract][Full Text] [Related]
19. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Darling HS; Bellmunt J
Expert Opin Biol Ther; 2019 Jul; 19(7):685-695. PubMed ID: 31046476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
